On Monday, Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s shares declined -10.45% to $102.18.
Valeant Pharmaceuticals International, Inc. (VRX) declared that chairman and chief executive officer J. Michael Pearson will be on a medical leave of absence, effective right away. The company’s board of directors has created an Office of the Chief Executive Officer, which will comprise Robert Chai-Onn, Executive Vice President and General Counsel, Dr. Ari Kellen, Executive Vice President and Company Group Chairman, and Robert Rosiello, Executive Vice President and Chief Financial Officer, to serve in an interim capacity.
In addition, the Board of Directors has created a Committee to oversee and support the Office of the CEO and will comprise Robert A. Ingram, Lead Independent Director, G. Mason Morfit, President, ValueAct Capital, and Howard B. Schiller, former Chief Financial Officer for Valeant.
Valeant confirmed last week that Mr. Pearson had recently been hospitalized and was being treated for a severe case of pneumonia.
“Our thoughts are with Mike and his family,” said Robert Ingram. “Out of respect, we will be honoring his family’s request for privacy and will not be commenting further on his condition at this time.”
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. The company offers Solodyn to treat red and pus-filled pimples of acne in patients, in addition to Ziana, Acanya, Atralin, Retin- A Micro, and ONEXTON gel; Wellbutrin XL for major depressive disorder in adults; Jublia for onychomycosis of the toenails; Xenazine for chorea; Targretin for Cutaneous T-Cell Lymphoma; Arestin, a subgingival sustained-release antibiotic; and PROVENGE for the treatment of prostate cancer.
Energy Transfer Partners LP (NYSE:ETP)’s shares dropped -1.65% to $33.40. The last trading range of Energy Transfer Partners LP(NYSE:ETP) ranges between $32.90 and $34.22. The EPS of the company stands at $0.42. The 52-week range shows that the stock reached higher at $66.85 while its lower range is $27.44 in the last 52-weeks. The average volume of the company is at 6.65 million with the Outstanding Shares of 501.95 million. The market capitalization of the company is $17.05 billion. The Beta of the company stands at 0.96 with the RSI (Relative Strength Index) of 47.79.
Energy Transfer Partners, L.P. engages in the natural gas midstream, and intrastate transportation and storage businesses in the United States. The company’s Intrastate Transportation and Storage segment transports natural gas from various natural gas producing areas, in addition to through its ET fuel system and HPL system.
Rowan Companies PLC (NYSE:RDC)‘s shares dipped -3.15% to $16.92. Rowan Companies PLC (NYSE:RDC) is now worth about $2.18 billion. The share price has made a -1.4% loss in the past 5 days and has lost -27.44% since 2015 kicked off. Analysts are forecasting EPS growth of -2.88% for next fiscal year. The stock trades with a beta of 1.45. The stock price is below by -11.27% as contrast to the average price over the last 200 days. The company has 51.90% gross margins.
Rowan Companies plc provides offshore oil and gas contract drilling services. It operates a fleet of 30 self-elevating mobile offshore jack-up drilling units, in addition to 3 ultra-deepwater drill ships.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.